The FDA Cleared ‘Wellness’ CGMs for Anyone—So Why Are Healthy People Panicking Over a 140 Reading?
OTC continuous glucose monitors put medical-looking numbers in wellness apps—without the clinical context that makes them meaningful. A single 140 mg/dL can feel like a verdict when it’s often just physiology.
By TheMurrow Editorial
May 18, 2026
Key Points
- 1Understand the shift: FDA-cleared OTC CGMs expand access, but they don’t turn wellness tracking into diabetes diagnosis or clinical certainty.
- 2Interpret 140 mg/dL carefully: timing and interstitial-fluid measurement can make normal post-meal physiology look like a scary “spike.”
- 3Use guardrails: focus on repeatable patterns, track context (meals, stress, exercise), and avoid extreme decisions from single graphs.
The first time a healthy person sees 140 mg/dL on a glucose graph, it can feel like a warning light.
Maybe it happens after a bowl of pasta. Maybe it’s a “clean” smoothie that suddenly looks less virtuous. The number sits there, bright and accusatory, and the app doesn’t always give you the one thing you actually need: context.
That tension—between raw data and real meaning—is why the U.S. Food and Drug Administration’s new wave of over-the-counter continuous glucose monitors matters far beyond diabetes care. These devices promise insight. They also risk turning ordinary physiology into a daily referendum on your self-control.
In 2024, the FDA opened a new door: glucose monitoring without a prescription. Millions of people who have never been told to track blood sugar can now buy sensors, wear them, and watch their glucose line rise and fall with every meal, meeting, and workout. The question is not whether this is “good” or “bad.” The question is whether consumers—and the companies selling to them—can treat glucose data like the nuanced signal it is, rather than a moral score.
When glucose tracking moves from the clinic to the checkout cart, context becomes the real product.
— — TheMurrow Editorial
The FDA’s OTC clearance: what happened, and what it does (and doesn’t) mean
On March 5, 2024, the FDA announced it had cleared the first over-the-counter continuous glucose monitor: the Dexcom Stelo Glucose Biosensor System. The agency described Stelo as an integrated CGM (iCGM) for adults 18 and older who do not use insulin—including people with diabetes managed with oral medications and people without diabetes who want to understand how diet and exercise affect glucose, according to the FDA’s press announcement. The headline feature was access: purchase without a health-care provider.
That distinction—cleared, not approved—sounds like regulatory hair-splitting until you’re the person staring at a graph at 11 p.m. Clearance is a formal FDA decision, but it typically signals a different regulatory pathway than “approval,” and it does not automatically imply the device is intended to diagnose disease. The FDA’s framing for Stelo is telling: it focuses on adult consumers not using insulin, and it explicitly excludes people with “problematic hypoglycemia.”
A few months later, on June 10, 2024, Abbott announced FDA clearance for two OTC systems: Libre Rio, aimed at type 2 diabetes not using insulin, and Lingo, positioned for health and wellness consumers (as reported by CNBC and echoed in Abbott’s communications). Abbott’s own support materials are blunt about the intended use: Lingo “is not intended for diagnosis or management of any disease, including diabetes.”
That sentence is doing heavy lifting. It draws a bright line between clinical care and consumer curiosity—while still placing medical-grade-looking numbers in a lifestyle context.
That distinction—cleared, not approved—sounds like regulatory hair-splitting until you’re the person staring at a graph at 11 p.m. Clearance is a formal FDA decision, but it typically signals a different regulatory pathway than “approval,” and it does not automatically imply the device is intended to diagnose disease. The FDA’s framing for Stelo is telling: it focuses on adult consumers not using insulin, and it explicitly excludes people with “problematic hypoglycemia.”
A few months later, on June 10, 2024, Abbott announced FDA clearance for two OTC systems: Libre Rio, aimed at type 2 diabetes not using insulin, and Lingo, positioned for health and wellness consumers (as reported by CNBC and echoed in Abbott’s communications). Abbott’s own support materials are blunt about the intended use: Lingo “is not intended for diagnosis or management of any disease, including diabetes.”
That sentence is doing heavy lifting. It draws a bright line between clinical care and consumer curiosity—while still placing medical-grade-looking numbers in a lifestyle context.
What “OTC” changes—and what it doesn’t
Over-the-counter access reduces friction: no prescription, no clinician gatekeeping, no insurance paperwork. It also removes the built-in interpreter most people have relied on—someone who can tell you whether a number is a problem, a pattern, or just Tuesday.
Abbott and Dexcom both include cautions across their materials that readings may not match symptoms and that confirmation with a fingerstick meter may be appropriate in some situations, according to Abbott’s OTC iCGM communications and public materials. That’s a clinical concept transplanted into consumer tech: sensors can be immensely useful, but they are not omniscient.
Abbott and Dexcom both include cautions across their materials that readings may not match symptoms and that confirmation with a fingerstick meter may be appropriate in some situations, according to Abbott’s OTC iCGM communications and public materials. That’s a clinical concept transplanted into consumer tech: sensors can be immensely useful, but they are not omniscient.
A glucose number without timing, context, and physiology is just a number—and numbers are easy to misunderstand.
— — TheMurrow Editorial
March 5, 2024
The FDA announced it cleared the first OTC continuous glucose monitor: Dexcom Stelo.
June 10, 2024
Abbott announced FDA clearance for two OTC systems: Libre Rio and Lingo.
Who OTC CGMs are actually for—and why the market is exploding
The FDA’s indication for Dexcom Stelo is specific: adults 18+, not on insulin, and not with “problematic hypoglycemia,” per the FDA. That’s a wide population: it includes many people with type 2 diabetes who are not using insulin, but also people with no diabetes diagnosis who simply want feedback on meals and activity.
The commercial push followed quickly. Dexcom launched Stelo for U.S. purchase on August 26, 2024, according to CNBC. Reported pricing: $99 for a month supply online or $89/month via subscription. Dexcom’s own investor release similarly cites an $89/month subscription and describes shipments as two sensors for up to 30 days of wear time. Those are consumer-product price points—closer to fitness wearables than medical devices—designed to make sustained tracking feasible.
Abbott, for its part, framed Lingo as a consumer “biowearable” in its communications, emphasizing wellness rather than disease management. Abbott’s U.S. availability announcement for Lingo is dated September 5, 2024. The sequencing matters: clearance in June, availability by early September. The market was not waiting.
The commercial push followed quickly. Dexcom launched Stelo for U.S. purchase on August 26, 2024, according to CNBC. Reported pricing: $99 for a month supply online or $89/month via subscription. Dexcom’s own investor release similarly cites an $89/month subscription and describes shipments as two sensors for up to 30 days of wear time. Those are consumer-product price points—closer to fitness wearables than medical devices—designed to make sustained tracking feasible.
Abbott, for its part, framed Lingo as a consumer “biowearable” in its communications, emphasizing wellness rather than disease management. Abbott’s U.S. availability announcement for Lingo is dated September 5, 2024. The sequencing matters: clearance in June, availability by early September. The market was not waiting.
The new user: motivated, data-literate—and medically untrained
Many buyers will be conscientious people who already optimize sleep, macros, or training load. They are accustomed to dashboards and trends. The problem is that glucose is different: it is deeply contextual and influenced by variables most people don’t track—stress, illness, timing, and individual biology.
In a clinical setting, CGMs often sit inside a framework: medication decisions, symptom histories, A1C, and clinician interpretation. In the wellness market, CGMs sit inside a different framework: self-experimentation, social media, and a powerful temptation to treat “stability” as virtue.
In a clinical setting, CGMs often sit inside a framework: medication decisions, symptom histories, A1C, and clinician interpretation. In the wellness market, CGMs sit inside a different framework: self-experimentation, social media, and a powerful temptation to treat “stability” as virtue.
$99/month
Reported one-month online price for Dexcom Stelo (CNBC).
$89/month
Reported subscription price for Dexcom Stelo; Dexcom describes two sensors for up to 30 days.
The 140 mg/dL problem: why one number creates so much confusion
The internet has turned 140 mg/dL into a kind of folk threshold—high enough to spark worry, low enough to spark debate. Search trends reveal the anxiety: “Is 140 blood sugar bad?” “What’s normal after meals?” People want a rule. CGMs deliver a stream instead of a rule.
Two complications collide here:
- Timing: A number after a meal means something different than a fasting number.
- Measurement type: CGMs typically measure glucose in interstitial fluid, not a fingerstick blood glucose reading, and the values can differ—especially when glucose is rising or falling quickly.
The research base in your outline flags a critical distinction: diagnosis thresholds are not the same as post-meal “spike” thresholds. Public health and diabetes organizations use specific categories for diagnosis (often based on labs), while CGM users are watching minute-by-minute changes after meals. Those worlds overlap, but they aren’t interchangeable.
Two complications collide here:
- Timing: A number after a meal means something different than a fasting number.
- Measurement type: CGMs typically measure glucose in interstitial fluid, not a fingerstick blood glucose reading, and the values can differ—especially when glucose is rising or falling quickly.
The research base in your outline flags a critical distinction: diagnosis thresholds are not the same as post-meal “spike” thresholds. Public health and diabetes organizations use specific categories for diagnosis (often based on labs), while CGM users are watching minute-by-minute changes after meals. Those worlds overlap, but they aren’t interchangeable.
Why CGMs make “spikes” feel more dramatic
CGMs are persuasive because they are vivid. A fingerstick is a single dot. A CGM is a story—peaks and valleys, cause-and-effect arcs, the sense that if you just tweak one input you can flatten the plot.
That can be empowering for some people, especially those with type 2 diabetes trying to understand food effects. For people without diabetes, it can also create unnecessary alarm. Without clinical targets, “normal” becomes whatever the app’s color scheme implies.
That can be empowering for some people, especially those with type 2 diabetes trying to understand food effects. For people without diabetes, it can also create unnecessary alarm. Without clinical targets, “normal” becomes whatever the app’s color scheme implies.
CGMs don’t just measure glucose. They measure your tolerance for ambiguity.
— — TheMurrow Editorial
A quick guide to “cleared, not approved”—and why companies keep repeating disclaimers
Readers tend to assume that if the FDA is involved, the device must be “medical” in the everyday sense: diagnostic, prescriptive, definitive. OTC CGMs are challenging because the hardware looks clinical, while the marketing often tilts toward lifestyle.
Abbott’s Lingo is explicit: not intended for diagnosis or management of any disease, including diabetes. That isn’t a throwaway line. It shapes what the product can promise—and what it expects the consumer to do with the data.
Dexcom Stelo’s FDA description is also carefully bounded: it’s for adults 18+ who do not use insulin, and the FDA’s announcement singles out people without diabetes who want to understand diet and exercise effects. The throughline is education and insight, not diagnosis.
Abbott’s Lingo is explicit: not intended for diagnosis or management of any disease, including diabetes. That isn’t a throwaway line. It shapes what the product can promise—and what it expects the consumer to do with the data.
Dexcom Stelo’s FDA description is also carefully bounded: it’s for adults 18+ who do not use insulin, and the FDA’s announcement singles out people without diabetes who want to understand diet and exercise effects. The throughline is education and insight, not diagnosis.
Why the disclaimers matter in real life
A CGM can be accurate enough to guide broad patterns, yet still require caution in edge cases:
- When symptoms don’t match the reading
- When glucose is changing rapidly
- When a decision would carry health consequences
Abbott’s public OTC iCGM communications note that CGM readings may not match symptoms or expectations and that a fingerstick meter may be appropriate for confirmation in some circumstances. That’s a clinically responsible caveat. It’s also a reminder that wellness use is not risk-free—especially when people start making big dietary changes based on a few dramatic charts.
- When symptoms don’t match the reading
- When glucose is changing rapidly
- When a decision would carry health consequences
Abbott’s public OTC iCGM communications note that CGM readings may not match symptoms or expectations and that a fingerstick meter may be appropriate for confirmation in some circumstances. That’s a clinically responsible caveat. It’s also a reminder that wellness use is not risk-free—especially when people start making big dietary changes based on a few dramatic charts.
Key Insight
OTC access removes the clinician “interpreter.” The risk isn’t just bad data—it’s confident misinterpretation of good data.
The promise: practical insight for type 2 diabetes—and for motivated “non-diabetics”
For adults with type 2 diabetes not using insulin, OTC CGMs like Stelo or Libre Rio could reduce barriers to data that many clinicians already consider useful. Seeing how a particular breakfast affects glucose can support behavior change in a way pamphlets don’t. It can also help people connect exercise with downstream glucose effects, making lifestyle advice feel less abstract.
For people without diabetes, the promise is more ambiguous: biofeedback as self-knowledge. The FDA explicitly included this population in its Stelo announcement—people who want to understand how diet and exercise affect glucose. That legitimizes wellness interest, at least as a matter of personal monitoring.
For people without diabetes, the promise is more ambiguous: biofeedback as self-knowledge. The FDA explicitly included this population in its Stelo announcement—people who want to understand how diet and exercise affect glucose. That legitimizes wellness interest, at least as a matter of personal monitoring.
Real-world example: the “healthy breakfast” surprise
Consider a common scenario: someone replaces a pastry breakfast with a large fruit-and-granola bowl. The CGM line rises higher than expected. The person concludes fruit is “bad” and cuts it out.
A more careful read might ask different questions: What was the portion size? What else was eaten? How long did it take to return toward baseline? Was there exercise later? Without that nuance, CGMs can turn into blunt instruments—encouraging restriction rather than understanding.
A more careful read might ask different questions: What was the portion size? What else was eaten? How long did it take to return toward baseline? Was there exercise later? Without that nuance, CGMs can turn into blunt instruments—encouraging restriction rather than understanding.
Where CGMs shine: pattern recognition, not perfection
The best consumer use tends to focus on:
- Comparing similar meals with small changes (adding protein or fiber)
- Testing timing (walking after eating)
- Noticing consistent responses rather than one-off peaks
The worst use tends to focus on chasing “flat lines,” a standard that may not be realistic—or even desirable—for everyone.
- Comparing similar meals with small changes (adding protein or fiber)
- Testing timing (walking after eating)
- Noticing consistent responses rather than one-off peaks
The worst use tends to focus on chasing “flat lines,” a standard that may not be realistic—or even desirable—for everyone.
The risk: anxiety, misinterpretation, and the problem of “targets” without a clinic
OTC CGMs arrive in a population that often lacks three things: clinical glucose targets, training, and a clinician to interpret data. That’s the editorial crux. When you move medical-style data into daily life without medical scaffolding, you change the psychology of eating and activity.
People can become hypervigilant. They can start treating meals like tests they’re trying not to fail. They can interpret normal fluctuations as danger, or use isolated readings to justify extreme diets.
Abbott’s decision to position Lingo explicitly as wellness—and to state it’s not for diagnosing or managing disease—anticipates this tension. So does the FDA’s careful labeling around Dexcom Stelo (18+, not on insulin, not problematic hypoglycemia). Regulators and manufacturers appear to agree on at least one point: OTC CGM users need guardrails.
People can become hypervigilant. They can start treating meals like tests they’re trying not to fail. They can interpret normal fluctuations as danger, or use isolated readings to justify extreme diets.
Abbott’s decision to position Lingo explicitly as wellness—and to state it’s not for diagnosing or managing disease—anticipates this tension. So does the FDA’s careful labeling around Dexcom Stelo (18+, not on insulin, not problematic hypoglycemia). Regulators and manufacturers appear to agree on at least one point: OTC CGM users need guardrails.
Practical takeaways for readers considering an OTC CGM
If you’re thinking about buying one, treat it like a tool for learning—not a referee.
- Decide what question you’re trying to answer. (“How does walking after dinner affect me?” beats “Is my glucose perfect?”)
- Track timing carefully. Note meals, exercise, stress, and sleep as best you can.
- Avoid big conclusions from single events. Look for repeated patterns across days.
- Use the manufacturer’s cautions seriously. If symptoms and readings don’t match, consider confirmation with a fingerstick meter as advised in public materials.
Those are not clinical directives. They’re basic data hygiene—necessary when the device is sold directly to consumers.
- Decide what question you’re trying to answer. (“How does walking after dinner affect me?” beats “Is my glucose perfect?”)
- Track timing carefully. Note meals, exercise, stress, and sleep as best you can.
- Avoid big conclusions from single events. Look for repeated patterns across days.
- Use the manufacturer’s cautions seriously. If symptoms and readings don’t match, consider confirmation with a fingerstick meter as advised in public materials.
Those are not clinical directives. They’re basic data hygiene—necessary when the device is sold directly to consumers.
OTC CGM data hygiene (before you spiral)
- ✓Decide what question you’re trying to answer
- ✓Track timing carefully (meals, exercise, stress, sleep)
- ✓Avoid big conclusions from single events
- ✓Use manufacturer cautions; confirm with a fingerstick meter when advised
The business story hiding in the health story: consumer wearables meet medical data
The price and rollout details signal ambition. Dexcom’s reported $99/month month-supply option and $89/month subscription (CNBC and Dexcom’s investor release) are designed for recurring consumer spend. Dexcom’s own description—two sensors for up to 30 days—sounds like a subscription-friendly cadence.
Abbott’s sequencing—FDA clearance announcement on June 10, 2024, then a U.S. availability announcement for Lingo on September 5, 2024—signals that the wellness CGM category is being built deliberately, with brand language calibrated for a mass audience.
Abbott’s sequencing—FDA clearance announcement on June 10, 2024, then a U.S. availability announcement for Lingo on September 5, 2024—signals that the wellness CGM category is being built deliberately, with brand language calibrated for a mass audience.
Multiple perspectives: empowerment vs. overreach
Supporters see democratization: people can access data previously reserved for clinical contexts, and they can discover how diet and exercise affect glucose—exactly the use case the FDA cited.
Skeptics see a familiar tech pattern: a biometric signal extracted from medicine, repackaged as self-improvement, and sold back to consumers who may be primed to worry. Both perspectives can be true. OTC CGMs could help many people. They could also create a new class of “worried well” users, refreshing apps after lunch the way some people refresh step counts.
The central issue is not whether CGMs are “accurate enough.” It’s whether the consumer ecosystem—apps, influencers, and product positioning—can teach interpretation as well as it teaches tracking.
Skeptics see a familiar tech pattern: a biometric signal extracted from medicine, repackaged as self-improvement, and sold back to consumers who may be primed to worry. Both perspectives can be true. OTC CGMs could help many people. They could also create a new class of “worried well” users, refreshing apps after lunch the way some people refresh step counts.
The central issue is not whether CGMs are “accurate enough.” It’s whether the consumer ecosystem—apps, influencers, and product positioning—can teach interpretation as well as it teaches tracking.
Editor’s takeaway
The central issue is not whether CGMs are “accurate enough.” It’s whether the consumer ecosystem can teach interpretation as well as it teaches tracking.
How to read your CGM like an adult: context, consistency, and restraint
If the wellness CGM era is going to be more than a fad, it needs a mature culture around it. Mature doesn’t mean humorless. It means recognizing that your body is not a spreadsheet and that metabolism is not a character test.
A simple framework for interpretation
Use three Cs:
- Context: What was happening—meal size, composition, timing, activity, stress?
- Consistency: Does the same meal produce a similar response across multiple days?
- Consequences: Are you using the data to make sensible adjustments—or spiraling into fear?
The FDA’s own language around OTC access focuses on expanding purchase options, not expanding diagnostic power. Abbott’s Lingo disclaimer makes the same point from the consumer side: wellness data is not disease management.
That boundary is worth respecting. If a CGM nudges you toward healthier habits—more walking, more balanced meals—great. If it nudges you toward compulsive restriction or constant worry, the device may be solving the wrong problem.
- Context: What was happening—meal size, composition, timing, activity, stress?
- Consistency: Does the same meal produce a similar response across multiple days?
- Consequences: Are you using the data to make sensible adjustments—or spiraling into fear?
The FDA’s own language around OTC access focuses on expanding purchase options, not expanding diagnostic power. Abbott’s Lingo disclaimer makes the same point from the consumer side: wellness data is not disease management.
That boundary is worth respecting. If a CGM nudges you toward healthier habits—more walking, more balanced meals—great. If it nudges you toward compulsive restriction or constant worry, the device may be solving the wrong problem.
The 3 Cs for interpreting your CGM
- 1.Context: What was happening—meal size, composition, timing, activity, stress?
- 2.Consistency: Does the same meal produce a similar response across multiple days?
- 3.Consequences: Are you using the data to make sensible adjustments—or spiraling into fear?
When to bring in a clinician
OTC access doesn’t mean you must go it alone. If you’re seeing patterns that concern you—or you have symptoms you can’t explain—medical guidance matters. OTC CGMs are designed to be accessible, but the body is still a medical object. Curiosity is not a substitute for care.
Conclusion: A new era of glucose data—and a new responsibility to interpret it well
The FDA’s 2024 clearances created a consumer category that didn’t exist before: OTC continuous glucose monitoring for adults who aren’t using insulin, including people without diabetes. Dexcom Stelo’s clearance (announced March 5, 2024) and Abbott’s clearances for Libre Rio and Lingo (announced June 10, 2024) make glucose data easier to buy than ever. Dexcom’s Stelo launch pricing—$99/month or $89/month subscription—makes it easier to keep wearing, not just to try once.
Access is not the same as understanding. The wellness market is about to learn what diabetes care has long known: glucose is a powerful metric that rewards humility. Numbers can teach. They can also mislead, especially when a single reading like 140 mg/dL becomes a verdict.
The real breakthrough won’t be the sensor. It will be the culture we build around it—one that treats glucose as information, not identity.
Access is not the same as understanding. The wellness market is about to learn what diabetes care has long known: glucose is a powerful metric that rewards humility. Numbers can teach. They can also mislead, especially when a single reading like 140 mg/dL becomes a verdict.
The real breakthrough won’t be the sensor. It will be the culture we build around it—one that treats glucose as information, not identity.
T
About the Author
TheMurrow Editorial is a writer for TheMurrow covering health & wellness.
Frequently Asked Questions
What did the FDA clear in 2024 for OTC CGMs?
On March 5, 2024, the FDA cleared the Dexcom Stelo Glucose Biosensor System, described as an iCGM for adults 18+ who do not use insulin, including people without diabetes who want to see how diet and exercise affect glucose. On June 10, 2024, Abbott announced FDA clearance for Libre Rio (for type 2 diabetes not using insulin) and Lingo (for wellness consumers).
Does “FDA cleared” mean the device is approved to diagnose diabetes?
Not necessarily. OTC clearance supports consumer access, but companies often draw explicit boundaries around diagnostic use. Abbott’s support materials state Lingo is not intended for diagnosis or management of any disease, including diabetes. The FDA’s Stelo description emphasizes adults not using insulin and positions it for understanding how diet and exercise affect glucose, not for diagnosing disease.
Who is Dexcom Stelo for, according to the FDA?
The FDA described Stelo as for adults 18 and older who do not use insulin, including people with diabetes managed with oral medications and people without diabetes who want to understand the effects of diet and exercise on glucose. The FDA also noted it is not intended for people with “problematic hypoglycemia.”
How much does an OTC CGM like Stelo cost?
Dexcom launched Stelo for purchase in the U.S. on August 26, 2024, with pricing reported by CNBC as $99 for a month supply online or $89/month subscription. Dexcom’s investor release also cites an $89/month subscription and describes two sensors for up to 30 days of wear time.
Is 140 mg/dL after a meal “bad”?
A single number like 140 mg/dL is easy to misread because meaning depends on timing (fasting vs. after eating), what you ate, and individual physiology. The article emphasizes that diagnostic thresholds are not the same as post-meal “spike” discussions that dominate CGM apps. If you’re concerned about repeated patterns, consider discussing them with a clinician rather than self-diagnosing from a graph.
Can CGM readings be wrong—or not match how I feel?
Yes. Manufacturer communications include cautions that CGM readings may not match symptoms or expectations, and that a fingerstick meter may be appropriate for confirmation in some circumstances. CGMs measure glucose in interstitial fluid, and readings can differ from blood glucose—especially when levels change quickly.
